Skip to content

Evaluation of Computer-Guided Secondary Alveolar Cleft Bone Grafting With and Without Platelet-Rich Fibrin

Evaluation of Computer-Guided Secondary Alveolar Cleft Bone Grafting With and Without Platelet-Rich Fibrin

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05422196
Enrollment
12
Registered
2022-06-16
Start date
2020-10-01
Completion date
2022-06-02
Last updated
2022-06-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alveolar Bone Grafting

Brief summary

This study aims at investigating the role of platelet-rich fibrin in alveolar cleft secondary grafting. This grafting is done from the patient's chin using a computer-guided stent that is customized for each patient, and the cleft volume is analysed at first to estimate the needed amount of bone to be harvested.

Interventions

PROCEDUREPlatelet-rich fibrin

Addition of platelet-rich fibrin into the cleft site.

Sponsors

Mansoura University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
9 Years to 14 Years
Healthy volunteers
Yes

Inclusion criteria

1. Healthy patients who are classified according to the American Society of Anesthesiologists (ASA) physical status classification as class I. 2. Patients seeking treatment and accepting to be enrolled in the study, so as their guardians. 3. Patients who will age 9-14 years old by the surgery day. 4. Patients with adequate chin bone volume that could be harvested without marked donor site morbidity, as pre-determined by cone beam computed tomography.

Exclusion criteria

1. Patients with systemic illness, i.e. ASA(22) classes II, III, IV, and V. 2. Patients with previously operated alveolar clefts and seeking revision for the same cleft. 3. Patients that wouldn't be able to attend the recalls. 4. Patients with other craniofacial anomalies and associated syndrome conditions. 5. Edentulous maxilla, atypical or non-described cleft diagnosis. 6. Patients with history of chemotherapy or radiotherapy.

Design outcomes

Primary

MeasureTime frameDescription
Closure of oronasal fistulaTen days postoperatively* By questioning the patient if there's a nasal regurgitation or not. * Qualitative outcome (positive or negative).
Volume of newly formed boneSix months postoperatively* By computerized measurement on the Cone-Beam Computed Tomography software. (Volume tool in Invesalius ® software (Invesalius, CTI, Brazil)). * Quantitative outcome (in cubic millimetres (mm3)).
Average density of newly formed boneSix months postoperatively* By computerized measurement on the Cone-Beam Computed Tomography software. (Average density tool in Invesalius ® software (Invesalius, CTI, Brazil)). * Quantitative outcome (in Hounsfield Units (HU)).

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026